• RAMYA R Department of Pharmacology, Vinayaka Missions Research Foundation, Salem, Tamil Nadu, India.
  • SHAJAHAN OM Clinical Pharmacologist and Basic Science Faculty for DNB, Vijaya Group of Hospitals, Chennai, Tamil Nadu, India.
  • ANAKHA KALADHARAN Pharm D Intern, K. K. College of Pharmacy, Chennai, Tamil Nadu, India.


 Objective: The objective of the study was to evaluate the renoprotective effect of cilnidipine by estimating urinary albumin and creatinine levels in mild-to-moderate hypertension (HTN) with type 2 diabetes mellitus (DM) and also evaluate the adverse drug profile of cilnidipine in the same patients.

Methods: This was a single-center, prospective, open-labeled, randomized study. A total of 60 patients of either gender aged between 30 and 60 with mild-to-moderate HTN with type 2 DM were included in the study. Urine albumin and urine creatinine were measured at day 1 and day 181. Blood pressure (BP) was measured in all visits. The drug cilnidipine at a dose of 10–20 mg oral was given and the corresponding improvement in the levels of urine albumin and other parameters was identified.

Results: There was a significant reduction in the mean systolic BP from 150.07±5.44 mmHg in visit 0 to 123.03±5.23 mmHg in visit 3. And also, there was a significant reduction in the mean diastolic BP from 95.5±8.15 mmHg in visit 0 to 80.8±2.42 mmHg in visit 3. The mean heart rate at visit zero was 76.71±4.86. At the end of 6 months of treatment, there was a significant reduction to 70.63±2.74. There was a significant reduction in the microalbuminuria from 66.62±8.39 to 38.8±6.45. The mean reduction was 27.56±10.25. There was no change in the creatinine level.

Conclusion: The study reveals that the drug cilnidipine is safe and effective in reducing the microalbuminuria and also effectively reduces BP in hypertensive patients. Hence, the drug cilnidipine can be safely administered to the patient with diabetes and HTN.

Keywords: Cilnidipine, Renoprotective, Microalbuminuria, Hypertension, Diabetes mellitus


1. The National High Blood Pressure Education Program Working Group. National high blood pressure education program working group report on hypertension in diabetes. Hypertension 1994;23:145-58.
2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703-13.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993;16:434-44.
4. Hu G, Jousilahti P, Tuomilehto J. Joint effects of history of hypertension at baseline and Type 2 diabetes at baseline and during follow-up on the risk of coronary heart disease. Eur Heart J 2007;28:3059-66.
5. Minami J, Ishimitsu T, Kawano Y, Numabe A, Matsuoka H. Comparison of 24-hour blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard. J Cardiovasc Pharmacol 1998;32:331-6.
6. Adake P, Somashekar HS, Mohammed Rafeeq PK, Umar D, Basheer B, Baroud K. Comparison of amlodipine with cilnidipine on antihypertensive efficacy and incidence of pedal edema in mild to moderate hypertensive individuals: A prospective study. J Adv Pharm Technol Res 2015?6:81-5.
7. Xu GL, Hui X, Wu HD, Ling Q. A meta-analysis of the efficacy and safety of cilnidipine in Chinese patients with mild to moderate essential hypertension. Afr J Pharm Pharmacol 2012?6:2393-9.
8. Kojima S, Shida M, Yokoyama H. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res 2004;27:379-85.
9. Tsuchihashi T, Ueno M, Tominaga M, Kajioka T, Onaka U, Eto K, et al. Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine. Clin Exp Hypertens 2005;27:583-91.
10. Tanaka M. The L/N-type calcium channel blocker, cilnidipine, reduces heart rate and albuminuria in patients with Type 2 diabetes. J Int Med Res 2010;38:602-10.
11. Das A, Kumar P, Kumari A, Chandra S, Gari M, Singh N, et al. Effects of cilnidipine on heart rate and uric acid metabolism in patients with essential hypertension. Cardiol Res 2016;7:167-72.
12. Soeki T, Kitani M, Kusunose K, Yagi S, Taketani Y, Koshiba K. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients. Hypertens Res 2012;35:1058-62.
13. Singh VK, Mishra A, Gupta KK, Misra R, Patel ML, Shilpa. Reduction of microalbuminuria in type-2 diabetes mellitus with angiotensin-converting enzyme inhibitor alone and with cilnidipine. Indian J Nephrol 2015;25:334-8.
14. Shajahan OM, Rajaram S, Ramya R, Ranga Bhashyam SR. A comparative study on efficacy and safety of amlodipine and cilnidipine in the treatment of mild to moderate essential hypertension. Natl J Basic Med Sci 2020;10:112-23.
88 Views | 41 Downloads
How to Cite
R, R., S. OM, and A. KALADHARAN. “EVALUATION OF RENOPROTECTIVE EFFECT OF CILNIDIPINE IN PATIENTS WITH MILD TO MODERATE HYPERTENSION AND TYPE 2 DIABETES MELLITUS – A PROSPECTIVE STUDY”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 14, no. 1, Jan. 2021, pp. 144-6, doi:10.22159/ajpcr.2021.v14i1.39962.
Original Article(s)